- New targeted therapies for non-small cell lung cancer
-
Lee EH, Kwak SH, Kim CY, Gwon HR, Kim EY, Chang YS
- KMID: 2541446
- J Korean Med Assoc.
- 2023 Mar;66(3):180-190.
- doi: 10.5124/jkma.2023.66.3.180
Background: Lung cancer is representative of a high frequency and high mortality disease and ranks at the top in incidence and mortality in Korea, when excluding thyroid cancer. In this... -
- CITED
-
- Close
- SHARE
-
- Close
- Adjuvant treatment for resectable non-small cell lung cancer
-
Lim JU
- KMID: 2541445
- J Korean Med Assoc.
- 2023 Mar;66(3):173-179.
- doi: 10.5124/jkma.2023.66.3.173
Background: Low-dose chest computed tomography is being increasingly used to screen for lung cancer, and the proportion of early diagnoses of patients with lung cancer in potentially resectable stages is... -
- CITED
-
- Close
- SHARE
-
- Close
- Current advances in the treatment of lung cancer with immune checkpoint inhibitors
-
Lee GW
- KMID: 2515932
- J Korean Med Assoc.
- 2021 May;64(5):333-341.
- doi: 10.5124/jkma.2021.64.5.333
Lung cancer is the leading cause of cancer-related deaths worldwide despite major advances in platinum-based chemotherapy and targeted therapy based on activating driving mutations. Immune checkpoint inhibitors (ICIs) have revolutionized... -
- CITED
-
- Close
- SHARE
-
- Close
- Targeted Therapy for Non-Small Cell Lung Cancer
-
Kim JS, Kang EJ
- KMID: 2501900
- Korean J Med.
- 2020 Apr;95(2):78-88.
- doi: 10.3904/kjm.2020.95.2.78
Treatment of progressive non-small cell lung cancer (NSCLC) has advanced remarkably, due in part to the development of targeted therapies. Several gene alterations, including EGFR, ALK, ROS1, and BRAF, play... -
- CITED
-
- Close
- SHARE
-
- Close
